INTANGIBLE ASSETS AND GOODWILL (Details) (USD $)	12 Months Ended			12 Months Ended		3 Months Ended			12 Months Ended	3 Months Ended	12 Months Ended	3 Months Ended		12 Months Ended		3 Months Ended				3 Months Ended				12 Months Ended		12 Months Ended		12 Months Ended		12 Months Ended		12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Sep. 30, 2012	Dec. 31, 2013 Ezogabine Retigabine	Dec. 31, 2013 Opana	Sep. 30, 2013 Developed Markets Ezogabine Retigabine	Sep. 30, 2013 Non-recurring basis Amortization and Impairments of Finite-lived Intangible Assets Ezogabine Retigabine	Sep. 30, 2013 Non-recurring basis Amortization and Impairments of Finite-lived Intangible Assets Developed Markets Ezogabine Retigabine	Dec. 31, 2013 Non-recurring basis Amortization and Impairments of Finite-lived Intangible Assets Developed Markets Ezogabine Retigabine	Sep. 30, 2013 Non-recurring basis Amortization and Impairments of Finite-lived Intangible Assets Developed Markets Discontinued OTC Skincare	Dec. 31, 2013 Non-recurring basis Amortization and Impairments of Finite-lived Intangible Assets Developed Markets Discontinued OTC Skincare	Mar. 31, 2013 Non-recurring basis Amortization and Impairments of Finite-lived Intangible Assets Developed Markets Opana	Sep. 30, 2013 Non-recurring basis In-process Research and Development Impairments and Other Charges Ezogabine Retigabine	Dec. 31, 2012 Acquired IPR&D	Dec. 31, 2013 Acquired IPR&D	Sep. 30, 2012 Acquired IPR&D U.S. Dermatology	Jun. 30, 2012 Acquired IPR&D U.S. Dermatology	Dec. 31, 2012 Acquired IPR&D U.S. Dermatology and U.S. Neurology and Other	Dec. 31, 2013 Corporate brand	Sep. 30, 2013 In Process Research and Development Non-recurring basis In-process Research and Development Impairments and Other Charges Ezogabine Retigabine	Dec. 31, 2013 In Process Research and Development Non-recurring basis In-process Research and Development Impairments and Other Charges Mapracorat	Dec. 31, 2013 In Process Research and Development Non-recurring basis In-process Research and Development Impairments and Other Charges Xerese	Sep. 30, 2013 In Process Research and Development Non-recurring basis In-process Research and Development Impairments and Other Charges Lacricert	Dec. 31, 2013 Product brands	Dec. 31, 2012 Product brands	Dec. 31, 2013 Corporate brand	Dec. 31, 2012 Corporate brand	Dec. 31, 2013 Product rights	Dec. 31, 2012 Product rights	Dec. 31, 2013 Partner relationships	Dec. 31, 2012 Partner relationships	Dec. 31, 2013 Out-licensed technology and other	Dec. 31, 2012 Out-licensed technology and other
Finite-lived intangible assets:
Weighted- Average Useful Lives (Years)	9 years																							9 years		15 years		8 years		4 years		6 years
Gross Carrying Amount	$ 14,398,719,000	$ 10,759,419,000																						$ 10,554,160,000	$ 7,968,318,000	$ 365,617,000	$ 284,287,000	$ 3,020,996,000	$ 2,110,350,000	$ 194,035,000	$ 187,012,000	$ 263,911,000	$ 209,452,000
Accumulated Amortization, Including Impairments	(3,827,408,000)	(1,997,626,000)																						(2,729,118,000)	(1,345,367,000)	(44,372,000)	(25,336,000)	(876,877,000)	(525,186,000)	(83,221,000)	(44,230,000)	(93,820,000)	(57,507,000)
Net Carrying Amount	10,571,311,000	8,761,793,000																						7,825,042,000	6,622,951,000	321,245,000	258,951,000	2,144,119,000	1,585,164,000	110,814,000	142,782,000	170,091,000	151,945,000
Indefinite-lived intangible assets:
Indefinite-lived intangible assets														546,876,000	579,311,000				1,697,538,000
Total intangible assets
Gross carrying amount	16,675,568,000	11,306,295,000
Net Carrying Amount	12,848,160,000	9,308,669,000
Impairment charges				551,600,000	22,200,000	551,600,000	551,600,000	551,600,000	551,600,000	10,000,000	10,000,000	22,200,000	93,800,000	24,700,000		133,400,000	4,300,000	24,700,000		93,800,000	14,400,000	8,800,000	27,300,000
Payment made for termination of research and development commitment			$ 12,000,000